Unione Europea - italiano - EMA (European Medicines Agency)

laboratorios hipra s.a. - vivo attenuato virus respiratorio sinciziale bovino (brsv), ceppo lym-56 - prodotti immunologici per bovidae, bestiame, live virali vaccini, virus respiratorio sinciziale bovino (brsv) - bestiame - immunizzazione attiva dei bovini per ridurre spargimento del virus respiratori e segni clinici causati da virus respiratorio sinciziale bovino infezione.

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

laboratorios farmaceuticos rovi s.a. - condroitinsolfato - condroitinsolfato

Italia - italiano - Ministero della Salute

laboratorios karizoo s.a. - amoxicillina triidrato - orale - amoxicillina triidrato - nd, amoxicillina triidrato (fu) 1000 mg/g - amoxicillin - avicoli, suini

Italia - italiano - Ministero della Salute

laboratorios hipra s.a. - proteina capsidica di circovirus suino di tipo 2(pcv2), mycoplasma hyopneumoniae inattivato - proteina capsidica di circovirus suino di tipo 2(pcv2) - 1.3 u. elisa; mycoplasma hyopneumoniae inattivato - 1.3 u. elisa - porcine circovirus + mycoplasma

Italia - italiano - Ministero della Salute

laboratorios karizoo s.a. - halofuginone lactate - orale - halofuginone lactate - nd, alofuginone 0,5 mg/ml - halofuginone - vitelli

Italia - italiano - Ministero della Salute

laboratorios hipra s.a. - vibrio (listonella) anguillarum, sierotipo o2beta, inattivato, vibrio (listonella) anguillarum, sierotipo o2alfa, inattivato, vibrio (listonella) anguillarum, sierotipo o1, inattivato - altro, iniettabile - vibrio (listonella) anguillarum; sierotipo o2beta; inattivato - 60 percentuale relativa di sopravvivenza; vibrio (listonella) anguillarum; sierotipo o2alfa; inattivato - 60 percentuale relativa di sopravvivenza; vibrio (listonella) anguillarum; sierotipo o1; inattivato - 60 percentuale relativa di sopravvivenza, vaccino vibrio anguillarum inattivato - pisces, others - pesci

Unione Europea - italiano - EMA (European Medicines Agency)

laboratorios hipra, s.a. - mycoplasma hyopneumoniae, strain 7304 (nexhyon), expressing the capsid protein of porcine circovirus type 2a, inactivated - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - pigs - for the active immunisation of pigs:to reduce lung lesions associated with porcine enzootic pneumonia caused by mycoplasma hyopneumoniae. also, to reduce the incidence of these lesions (as observed in field studies). to reduce viraemia, virus load in lungs and lymphoid tissues and the duration of the viraemic period associated with diseases caused by porcine circovirus type 2 (pcv2). efficacy against pcv2 genotypes a, b and d has been demonstrated in field studies. to reduce culling rate and the loss of daily weight gain caused by mycoplasma hyopneumoniae and/or pcv2 related diseases (as observed at 6 months of age in field studies). mycoplasma hyopneumoniae: onset of immunity: 3 weeks after vaccinationduration of immunity: 23 weeks after vaccinationporcine circovirus type 2:onset of immunity: 2 weeks after vaccinationduration of immunity: 22 weeks after vaccinationin addition, a reduction in nasal and faecal shedding and the duration of nasal excretion of pcv2 was demonstrated in animals challenged at 4 weeks and at 22 weeks after vaccination.

Italia - italiano - Ministero della Salute

laboratorios karizoo s.a. - amoxicillina triidrato - amoxicillina triidrato - 172.2 mg/ml - amoxicillin

Unione Europea - italiano - EMA (European Medicines Agency)

laboratorios hipra, s.a. - clostridioides difficile toxoid a, clostridioides difficile toxoid b, clostridium perfringens, type a, alpha toxoid - immunologicals for suidae, inactivated bacterial vaccines for pigs, clostridium - pigs - for the passive immunisation of neonatal piglets by means of the active immunisation of breeding sows and gilts:- to prevent mortality and reduce clinical signs and macroscopic lesions caused by clostridioides difficile toxins a and b. - to reduce clinical signs and macroscopic lesions caused by clostridium perfringens type a, alpha toxin.

Unione Europea - italiano - EMA (European Medicines Agency)

laboratorios farmacéuticos rovi, s.a. - risperidone - schizofrenia - psicolettici - treatment of schizophrenia in adults for whom tolerability and effectiveness has been established with oral risperidone.